ELIAS News2020-05-03T19:08:59-06:00

News & Updates

Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy

Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience [...]

July 14th, 2020|

ELIAS Animal Health Appoints Dr. Brian Andresen as Sales and Marketing Leader

Olathe, Kan., June 8, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment of Brian Andresen, DVM as Vice President of Sales & Marketing. Dr. Andresen brings an extensive sales and marketing background to the company, including the development, commercialization, launch, and leadership of animal health, human pharmaceutical, and biopharmaceutical brands. “With experience in both veterinary science and sales and marketing, Brian brings a unique and well-rounded perspective of the animal health products market,” said ELIAS CEO, Tammie Wahaus. “I am thrilled to add Brian to this team [...]

June 8th, 2020|

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial [...]

May 28th, 2020|
Go to Top